Romidepsin is an active HDACi that could not only enhance NKG2D ligand expression in cancer cells but also activate NKG2D expression in NK cells, so when Burkitt lymphoma cells were treated with romidepsin in advance, they would be easier to kill by CD20 CAR-NK cells. This evidence concerns the gene KLRK1 and cancer.